BRIEF published on 07/15/2025 at 09:05, 10 months 2 days ago AATec Medical et Northway Biotech forment un partenariat pour le développement de la production d'ATL-105 Partenariat ATL-105 Fabrication De Produits Biologiques Maladies Pulmonaires Thérapie Respiratoire
BRIEF published on 07/15/2025 at 09:05, 10 months 2 days ago AATec Medical and Northway Biotech Form Partnership for ATL-105 Production Development Partnership ATL-105 Biologics Manufacturing Lung Diseases Respiratory Therapy
PRESS RELEASE published on 07/15/2025 at 09:00, 10 months 2 days ago AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases AATec Medical and Northway Biotech announce partnership to develop industrial production process for ATL-105 targeting lung diseases Partnership AATec Medical ATL-105 Lung Diseases Northway Biotech
BRIEF published on 04/15/2025 at 11:09, 1 year 1 month ago AATec Medical obtient 4 millions d'euros pour le développement de médicaments respiratoires Biotechnologie Financement Essais Cliniques Développement De Médicaments Maladies Respiratoires
BRIEF published on 04/15/2025 at 11:09, 1 year 1 month ago AATec Medical Secures EUR 4 Million for Respiratory Drug Development Biotechnology Funding Clinical Trials Drug Development Respiratory Diseases
PRESS RELEASE published on 04/15/2025 at 11:04, 1 year 1 month ago AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development AATec Medical secures EUR 4 million funding to advance lead respiratory drug candidate, ATL-105, for clinical development to treat non-CF bronchiectasis by 2026 Clinical Development AATec Medical Non-CF Bronchiectasis EUR 4 Million Respiratory Drug Candidate
BRIEF published on 09/18/2024 at 10:05, 1 year 7 months ago AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board Scientific Advisory Board AATec Medical James Chalmers Bronchiectasis Recombinant AAT
BRIEF published on 09/18/2024 at 10:05, 1 year 7 months ago AATec Medical accueille le professeur James Chalmers au sein de son conseil consultatif scientifique AATec Medical Conseil Consultatif Scientifique James Chalmers Bronchectasie AAT Recombinante
PRESS RELEASE published on 09/18/2024 at 10:00, 1 year 7 months ago AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board AATec Medical welcomes Professor James Chalmers, a renowned expert in respiratory medicine, to its Scientific Advisory Board to advance product development in non-CF bronchiectasis Scientific Advisory Board AATec Medical Professor James Chalmers Respiratory Medicine Non-CF Bronchiectasis
BRIEF published on 07/24/2024 at 10:05, 1 year 9 months ago AATec Medical Makes Significant Strides in First Year of Operations Biotechnology Clinical Trials AATec Medical ATL-105 Inflammatory Lung Diseases
Published on 05/16/2026 at 01:15, 2 days 6 hours ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 2 days 7 hours ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 2 days 8 hours ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/18/2026 at 07:00, 15 minutes ago Sonova delivers strong FY 2025/26 results with continued market outperformance and increased profitability
Published on 05/18/2026 at 07:00, 15 minutes ago Portfolio Update - Impact of planned SpaceX IPO on Matador Secondary Private Equity AG
Published on 05/18/2026 at 06:30, 45 minutes ago Helvetica Swiss Living Fund – Review of a Capital Increase
Published on 05/18/2026 at 06:30, 45 minutes ago Helvetica Swiss Living Fund – examen d’une augmentation de capital
Published on 05/16/2026 at 16:08, 1 day 15 hours ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 15:08, 2 days 16 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 16 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 21 hours ago Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 22 hours ago Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 13 hours ago ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
